driver payg inflect
pharmaci continu prove disrupt reduc barrier
access pull patient mix guidanc
rais time year appear achiev ex us
issu transient lrp continu look conserv
although expect signific invest
beat revenu rais guidanc consecut
quarter deliv sale vs mse beat
driven strength across us intern omnipod preview
expect beat base momentum stabil deliv
pt corpor deceler cc basi us omnipod sale
vs mse beat driven on-going inflect
payg pharmaci model third consecut quarter record new us
patient us pharmaci omnipod sale
commentari notabl built inflect segment seen
intern omnipod sale came vs mse
beat commerci traction continu post-ypsom benefit
stock manag rais top-lin guidanc
revenu roughli beat line model gross
margin fell sequenti compani
ramp invest first two acton manufactur line continu
expect deliv similar gross margin rel
model year manag maintain oper expens
guidanc y/i increas compani reinvest sale upsid pleas
see exhibit reconcili full result vs mse
guidanc implic look still solid underli basi
outlin expect us omnipod growth
impli pt sequenti momentum deceler us
growth follow pt us momentum acceler quarter see
guidanc prudent achiev intern omnipod manag
expect revenu absolut basi reflect
report growth although cc growth cc
growth impli pt momentum deceler cc basi
medic technolog unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
reflect pull-forward distributor order time
ex-u busi distributor channel manag
confid underli ex-u busi fundament stabl
messag around high-teen low-twenti ex-u growth outlook
move piec confid manag abil
deliv top-line growth corpor level impli
lrp see continu model us omnipod growth
ex-u omnipod growth drug deliveri declin model
growth although trend well vet longer core
debat sens gross oper margin expans back-half
weight lrp compani second third acton
manufactur line ramp come year model
bp gm expans follow bp
compani scale product capabl model bp om
expans previous sens
manag plan continu invest heavili support futur
product iter beyond horizon well commerci infrastructur pleas
see exhibit model chang
horizon deck concern launch disrupt manag
re-affirmed horizon ap pivot begin within come month
launch slate sens trial run month
data present like ada confid manag abil
meet timelin especi given breakthrough devic design
fda recent ace approv interoper see manag
focu scale acton manufactur line throughout see
horizon increment growth driver oppos disruptor
seen lesser extent control iq see horizon function
competit like well control-iq
better form factor set stage competit integr offer
pharmaci importantli manag emphas shift mix toward
us intens popul patient base
given omnipod eas use payg model expect
continu focu penetr popul drive relief
competit concern vs pump player come year horizon
lrp continu look conserv pt discuss follow
ada see earn see recent healthcar confer
see visibl path increas
mark meaning inflect growth provid evid sustain
remain confid manag abil meet lrp target especi
given market expans natur share captur opportun embed
payg shift pharmaci increas opportun penetr
popul model sale impli top-line
growth compound-annual-growth-rate remain confid guidanc mid-teen
om model om rais price target
reflect multipl ev sale
long-term omnipod growth sustain
long-term omnipod growth sustain
price target reflect ev sale multipl
base case slightli high growth smid cap
ev/sal support dcf analysi
ev/sal support dcf analysi
post-ypsom anniversari ex us reacceler underli
growth medicar shift pharmaci acceler us growth ap
competitor prove market expans immateri omnipod growth
expand larger type market disclosur
addit drug deliveri deal materi increas valu busi
greater scale oper effici pharmaci channel drive om
next year
ev/sal support dcf analysi
ev/sal support dcf analysi
ex-u growth improv meaning follow anniversari ypsome us
growth remain driven shift pharmaci payg
model mdi pediatr posit insul omnipod ap
competitor risk remain path sale gm
clear like floor dash roll horizon ap launch
ev/sal support dcf analysi
ev/sal support dcf analysi
pediatr mdi adopt medicar expans fail off-set
competit headwind dash horizon adopt modest ap timelin
slip drug deliveri sale declin drastic expect path greater
profit becom less clear greater invest requir support
remain comfort near-term
revenu trend omnipod somewhat
de-risk competit ap launch given
mdi posit shift pharmaci
drive near term volatil
longer term driver growth path
revenu becom clear driven
channel shift pharmaci medicare/unh
ex us growth
us new anima patient sustain mid-teen
growth us
profit concern
direct distribut ex us shift
pharmaci show us path gm
medicar shift
pharmaci sustain us growth direct
path profit improv
direct distribut ex us shift
pharmaci us
dash roll provid
foundat cgm integr ap
dash roll-out on-going us ex-
risk achiev price
market share ap competitor ii ex-u see
volatil follow move away
path sustain profit becom less
ypsome transit ii disclosur
abil drive manufactur oper
million except ep
sale
sale
sale
sale
sale
sale
sale
sale
dollar million except per share data
dollar million except per share data
dollar million except per share data
cash equival
prepaid expens current asset
accru expens current liabil
current portion long-term debt
current portion capit leas oblig
lt debt net discount
dollar million except per share data
non-cash interest expens
loss extinguish long-term debt
provis bad debt
net chang work capit
proce purchas short term invest
proce divestitur
net invest
princip payment capit leas oblig
proce issuanc common stock
payment withhold tax connect
vest restrict stock unit
proce issuanc long-term debt net
repay long-term debt
net financ
effect exchang rate chang cash
begin period
end period
